Autor: |
Tao Zhang, Xu Wang, Yucheng Zhang, Tingting Feng, Yujie Zhou, Lin Zhao |
Jazyk: |
angličtina |
Rok vydání: |
2024 |
Předmět: |
|
Zdroj: |
Frontiers in Cardiovascular Medicine, Vol 11 (2024) |
Druh dokumentu: |
article |
ISSN: |
2297-055X |
DOI: |
10.3389/fcvm.2024.1385943 |
Popis: |
BackgroundPatients with chronic obstructive pulmonary disease (COPD) after acute coronary artery syndrome (ACS) are at an increased risk of heart failure and death. However, β-blockers have been underused in this population group due to concerns of adverse reactions.ObjectiveThis study aims to investigate the β-blocker prescription at admission and its impact on the in-hospital outcomes in patients with COPD after ACS in a Chinese national cohort.MethodsAmong 113,650 patients with ACS enrolled in the national registry of the Improving Care for Cardiovascular Disease in China between November 2014 and July 2019, a total of 1,084 ACS patients with COPD were included in this study. The primary endpoint was in-hospital mortality, and the secondary endpoint was the composite of in-hospital all-cause death and heart failure.ResultsEarly oral β-blocker therapy was administered to 49.8% of patients. The Kaplan–Meier analysis showed that the early β-blocker treatment group had lower all-cause mortality (0.9% vs. 2.9%; P |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|